Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the recipient of some unusual options trading on Wednesday. Traders bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the average daily volume of 53 put options.
Institutional investors have recently bought and sold shares of the stock. Arcadia Investment Management Corp MI purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $41,000. Spire Wealth Management bought a new stake in Maravai LifeSciences during the fourth quarter valued at about $71,000. American International Group Inc. raised its holdings in Maravai LifeSciences by 25.0% during the third quarter. American International Group Inc. now owns 1,994 shares of the company’s stock valued at $98,000 after acquiring an additional 399 shares during the period. Nkcfo LLC bought a new stake in Maravai LifeSciences during the fourth quarter valued at about $101,000. Finally, SG Americas Securities LLC purchased a new position in shares of Maravai LifeSciences during the fourth quarter valued at about $112,000. Institutional investors own 52.96% of the company’s stock.
MRVI has been the subject of several recent analyst reports. Zacks Investment Research raised Maravai LifeSciences from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a research note on Wednesday, February 2nd. Morgan Stanley cut their target price on Maravai LifeSciences from $59.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, February 25th. Finally, Robert W. Baird dropped their price target on Maravai LifeSciences from $60.00 to $48.00 in a report on Thursday, February 24th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Maravai LifeSciences has a consensus rating of “Buy” and an average price target of $49.20.
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last released its quarterly earnings results on Wednesday, February 23rd. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.07. The business had revenue of $228.44 million during the quarter, compared to analyst estimates of $208.09 million. Maravai LifeSciences had a return on equity of 105.25% and a net margin of 22.83%. Maravai LifeSciences’s quarterly revenue was up 132.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.13 EPS. On average, equities research analysts predict that Maravai LifeSciences will post 1.76 EPS for the current year.
Maravai LifeSciences Company Profile (Get Rating)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- 3 Ways to Invest in 5G Growth
- Sell-Side Activity Drives Proctor & Gamble Higher
- Google Upgraded Ahead Of Earnings
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.